CSIMarket
 
Eli Lilly And Company  (LLY)
Other Ticker:  
 
 
Price: $762.6600 $8.49 1.126%
Day's High: $769.68 Week Perf: 1.02 %
Day's Low: $ 758.25 30 Day Perf: 0.64 %
Volume (M): 2,521 52 Wk High: $ 800.78
Volume (M$): $ 1,922,895 52 Wk Avg: $541.04
Open: $762.28 52 Wk Low: $323.26



 Market Capitalization (Millions $) 689,076
 Shares Outstanding (Millions) 904
 Employees 35,000
 Revenues (TTM) (Millions $) 34,124
 Net Income (TTM) (Millions $) 5,240
 Cash Flow (TTM) (Millions $) 752
 Capital Exp. (TTM) (Millions $) 3,448

Eli Lilly And Company
We discover, develop, manufacture, and sell products in one significant business segment'pharmaceutical products. Operations of our animal health business segment are not material to our financial statements. We manufacture and distribute our products through owned or leased facilities in the United States, Puerto Rico, and 17 other countries. Our products are sold in approximately 140 countries.

Most of the products we sell today were discovered or developed by our own scientists, and our success depends to a great extent on our ability to continue to discover and develop innovative new pharmaceutical products. We direct our research efforts primarily toward the search for products to prevent and treat human diseases. We also conduct research to find products to treat diseases in animals and to increase the efficiency of animal food production.

In the United States, we distribute pharmaceutical products principally through independent wholesale distributors. Our marketing policy is designed to assure that products and relevant medical information are immediately available to physicians, pharmacies, hospitals, and appropriate health care professionals throughout the country. Three wholesale distributors in the United States ' AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation. No other distributor accounted for more than 10'percent of consolidated net sales. We also sell pharmaceutical products directly to the United States government and other manufacturers, but those sales are not material.

We promote our major pharmaceutical products in the United States through sales representatives who call upon physicians, wholesalers, hospitals, managed-care organizations, retail pharmacists, and other health care professionals. We advertise in medical and drug journals, distribute literature and samples of certain products to physicians, and exhibit at medical meetings. In addition, we advertise certain products directly to consumers in the United States and we maintain web sites with information about all our major products. Divisions of our sales force are dedicated to product lines or practice areas, such as primary care, neuroscience, diabetes care, acute care, endocrinology, and oncology. We have entered into licensing arrangements under which other companies market certain products manufactured by us, such as Darvon, Sarafem, Axid, Keftab, Lorabid, and Permax.

Large purchasers of pharmaceuticals, such as managed-care groups and government and long-term care institutions, account for a significant portion of total pharmaceutical purchases in the United States. We have created special sales groups to service managed-care organizations, government and long-term care institutions, hospital contract administrators, and certain retail pharmacies. In response to competitive pressures, we have entered into arrangements with a number of these organizations providing for discounts or rebates on one or more Company products or other cost-sharing arrangements.

Outside the United States, we promote our pharmaceutical products primarily through sales representatives. While the products marketed vary from country to country, neuroscience products constitute the largest single group in total sales. Distribution patterns vary from country to country. In most countries, we maintain our own sales and distribution organizations. In some countries, however, we market our products through independent distributors.

Raw Materials and Product Supply

Most of the principal materials we use in our manufacturing operations are available from more than one source. We obtain certain raw materials principally from only one source. In addition, three of our significant products are manufactured by others: Actos by Takeda; ReoPro by Centocor; and Xigris by Lonza Biologics (bulk product) and DSM, N.V. (finished product). If we were unable to obtain certain materials from present sources, we could experience an interruption in supply until we established new sources or, in some cases, implemented alternative processes.

Competition

Our pharmaceutical products compete with products manufactured by many other companies in highly competitive markets throughout the world. Our animal health products compete on a worldwide basis with products of pharmaceutical, chemical, and other companies that operate animal health divisions or subsidiaries.

Important competitive factors include product efficacy, safety, and ease of use, price and demonstrated cost-effectiveness, marketing effectiveness, service, and research and development of new products and processes. If competitors introduce new products, delivery systems or processes with therapeutic or cost advantages, our products can be subject to progressive price reductions or decreased volume of sales, or both. Most new products that we introduce must compete with other products already on the market or products that are later developed by competitors. Manufacturers of generic pharmaceuticals typically invest far less in research and development than research-based pharmaceutical companies and therefore can price their products significantly lower than branded products. Accordingly, when a branded product loses its market exclusivity, it normally faces intense price competition from generic forms of the product. In many countries outside the United States, patent protection is weak or nonexistent and we must compete with generic or 'knockoff' versions of our products.



   Company Address: Lilly Corporate Center Indianapolis 46285 IN
   Company Phone Number: 276-2000   Stock Exchange / Ticker: NYSE LLY
   


Customers Net Income fell by LLY's Customers Net Profit Margin fell to

-11.5 %

2.66 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -1.34%    
ABT   -6.89%    
BMY   -5.17%    
JNJ   -3.67%    
MRK   -0.99%    
PFE   -1.04%    
• View Complete Report
   



Eli Lilly And Company

Eli Lilly And Company Sees Income Surge by 12.87% in Q4 of 2023


Eli Lilly And Company, a major player in the pharmaceutical industry, experienced a decline of 14.42% in its shares during February 2024. This brought the share price down to 27.6% during the first quarter of the year. However, despite this setback, LLY shares seem to be gaining momentum and are only 4.9% away from reaching their 52-week high of $794.47.
These developments in the stock market are worth analyzing in light of the recently released financial results of Eli Lilly And Company. In the fiscal fourth quarter of 2023, the company reported significant growth in net profit per share, which increased by 12.87% to $2.42 compared to $2.15 in the previous year. Net profit per share also turned positive after a negative value of $-0.06 in the prior quarter.

Eli Lilly And Company

Eli Lilly And Company Faces Challenges as Surge in Revenue Fails to Translate Into Profitability During Q3 2023 Earnings Season

Eli Lilly And Company: A Strong Turnaround in the Third Quarter
Eli Lilly And Company, a major pharmaceutical preparations company, recently announced its third-quarter earnings for 2023, and the results were nothing short of remarkable. Despite slipping into a deficit of $-0.06 per share, the company experienced a surge in revenue by 36.836%, reaching an impressive $9.50 billion compared to the same reporting period last year.
In the preceding quarter, Eli Lilly And Company achieved a revenue of $8.31 billion and $1.95 per share, making the current results a significant improvement. Although the company faced a net deficit of $-57.400 million in the third quarter of 2023, compared to a net income of $1,451.700 million in the same period the previous year, it is important to note the positive trajectory the company is on.

Eli Lilly And Company

Eli Lilly And Company Reports Impressive Earnings Growth in Q2 2023, Demonstrating Strong Performance and Market Success

Eli Lilly And Company (LLY) has impressed investors with its strong financial performance in the fiscal interval ending June 30, 2023. The company experienced significant growth in both income per share and revenue, showcasing its ability to capitalize on market opportunities.
LLY's income per share witnessed a remarkable year-on-year increase of 85.71%, surging to $1.95 per share. This growth demonstrates the company's successful implementation of strategic initiatives and strong operational efficiency. Additionally, the company's revenue soared by 28.115% to reach $8.31 billion, reflecting the successful execution of its sales and marketing strategies.






 

Eli Lilly's Segments
 
Neurosciences
 Segment     of total Revenue
Endocrinology
 Segment     of total Revenue
Oncology
 Segment     of total Revenue
Animal health
 Segment     of total Revenue
Cardiovascular
 Segment     of total Revenue
Other pharmaceutical
 Segment     of total Revenue
Zyprexa
 Segment     of total Revenue
Humulin
 Segment     of total Revenue
Humalog
 Segment     of total Revenue
Evista
 Segment     of total Revenue
Cymbalta
 Segment     of total Revenue
Strattera
 Segment     of total Revenue
Alimta
 Segment     of total Revenue
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Eli Lilly does not provide revenue guidance.

Earnings Outlook
Eli Lilly And Company issued annual earnings guidance on

 
Geographic Revenue Dispersion
United States
Europe
Other foreign countries




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com